<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999218</url>
  </required_header>
  <id_info>
    <org_study_id>8835-002</org_study_id>
    <secondary_id>2013-003582-34</secondary_id>
    <secondary_id>B1521013</secondary_id>
    <nct_id>NCT01999218</nct_id>
  </id_info>
  <brief_title>Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of the addition of ertugliflozin
      (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who
      have inadequate glycemic control on metformin. The primary hypothesis of this study is that
      after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with
      the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in
      participants treated with the addition of glimepiride.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the trial will be up to approximately 122 weeks. This will include a 1-week
      screening period, an up to 13-week wash-off/titration/dose stabilization period, a 2-week
      placebo run-in period, a 104-week double-blind, active comparator-controlled treatment
      period, and a post-treatment telephone contact 14 days after the last dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2013</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106</measure>
    <time_frame>Up to Week 106</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104</measure>
    <time_frame>Up to Week 104</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1326</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride up to 8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8835</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 10 mg</intervention_name>
    <description>Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.</description>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <other_name>MK-8355</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimerpiride</intervention_name>
    <description>Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose</description>
    <arm_group_label>Glimepiride up to 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertugliflozin</intervention_name>
    <description>Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Glimepiride up to 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Glimepiride</intervention_name>
    <description>Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants are to remain on their stable doses of metformin (oral, &gt;=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin &lt;1500 at screening are up-titrated to &gt;= 1500 daily.</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Glimepiride up to 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Open label, oral, once daily, rescue medication as required.</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 15 mg</arm_group_label>
    <arm_group_label>Glimepiride up to 8 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of T2DM in accordance to American Diabetes Association guidelines

          -  On metformin monotherapy or metformin in combination with a single allowable
             anti-hyperglycemic agent (AHA), DPP-4 inhibitors, meglitinides and AGIs are listed as
             allowable AHAs along with sulfonylureas prior to study participation.

          -  Body Mass Index (BMI) ≥18.0 kg/m^2

          -  Male or female not of reproductive potential

          -  If a female of reproductive potential, agree to remain abstinent or to use (or have
             their partner use) 2 acceptable combinations of birth control while participating in
             the trial and for 14 days after the last use of study drug.

        Exclusion Criteria:

          -  History or presence of type 1 diabetes mellitus or a history of ketoacidosis

          -  History of other specific types of diabetes (eg, genetic syndromes, secondary
             pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and
             post-organ transplant).

          -  A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2)
             inhibitor

          -  Use of the following prohibited therapeutic agents within 12 weeks of study
             participation: insulin, injectable anti-hyperglycemic agents, pioglitazone or
             rosiglitazone, another SGLT2 inhibitor, bromocriptine (Cycloset®), colesevelam
             (Welchol®), and any other non-approved anti-hyperglycemic therapy

          -  Known hypersensitivity or intolerance to metformin or glimepiride

          -  On a weight-loss program or medication or medication associated with weight changes
             and is not weight-stable (&gt;=5% change in body weight in the last 6 months)

          -  History of bariatric surgery less than 12 months prior to study participation

          -  History of myocardial infarction, unstable angina, arterial revascularization, stroke,
             transient ischemic attack, or New York Heart Association (NYHA) functional class
             III-IV heart failure within 3 months of study participation

          -  Active, obstructive uropathy or an indwelling urinary catheter

          -  A history of malignancy ≤5 years prior to study participation, except for adequately
             treated basal or squamous cell skin cancer or in situ cervical cancer

          -  Known history of Human Immunodeficiency Virus (HIV)

          -  Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells

          -  A medical history of active liver disease (other than non-alcoholic hepatic
             steatosis), including chronic active hepatitis B or C (assessed by medical history),
             primary biliary cirrhosis, or symptomatic gallbladder disease

          -  Any clinically significant malabsorption condition

          -  Being treated for hyperthyroidism, or on thyroid replacement therapy that has not been
             at a stable dose for at least 6 weeks prior to study participation

          -  Previous randomization in a study with ertugliflozin

          -  Participation in other studies involving investigational drug(s) within 30 days of
             study participation and/or during the pre-randomization period

          -  A surgical procedure within 6 weeks prior to study participation or planned major
             surgery during the trial

          -  A positive urine pregnancy test

          -  Pregnant or breast-feeding, or expecting to conceive during the trial, including 14
             days following the last dose of study drug

          -  Undergoing hormonal therapy in preparation to donate eggs during the period of the
             trial, including 14 days following the last dose of study drug

          -  Consumption of more than 2 alcoholic drinks per day or engages in binge drinking

          -  Donation of blood or blood products within 6 weeks of study participation or plans to
             donate blood or blood products at any time during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>April 10, 2018</results_first_submitted>
  <results_first_submitted_qc>April 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2018</results_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted in 16 countries at 232 trial centers in Argentina, Canada, Czech Republic, Hungary, South Korea, Lithuania, Mexico, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Taiwan, Ukraine, and the United States.</recruitment_details>
      <pre_assignment_details>A total of 1326 participants were randomized. Ten randomized participants from one trial site were excluded from all final analyses (Week 104 and beyond), and one randomized participant did not receive treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
        </group>
        <group group_id="P2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
        </group>
        <group group_id="P3">
          <title>Glimepiride</title>
          <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="441"/>
                <participants group_id="P3" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="448"/>
                <participants group_id="P2" count="440"/>
                <participants group_id="P3" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Site Issue</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="435"/>
                <participants group_id="P3" count="435"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="339"/>
                <participants group_id="P2" count="340"/>
                <participants group_id="P3" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated By Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moves</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Creatinine/eGFR</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treated but excluded at 1 trial site</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
        </group>
        <group group_id="B2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
        </group>
        <group group_id="B3">
          <title>Glimepiride</title>
          <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="448"/>
            <count group_id="B2" value="441"/>
            <count group_id="B3" value="437"/>
            <count group_id="B4" value="1326"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All randomized participants</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="441"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="9.7"/>
                    <measurement group_id="B2" value="58.0" spread="9.9"/>
                    <measurement group_id="B3" value="57.8" spread="9.2"/>
                    <measurement group_id="B4" value="58.2" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>All randomized participants</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="441"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="684"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="224"/>
                    <measurement group_id="B4" value="642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>All randomized participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="441"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="318"/>
                    <measurement group_id="B4" value="966"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <population>All randomized participants and treated participants.</population>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="440"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.9" spread="18.9"/>
                    <measurement group_id="B2" value="85.6" spread="19.1"/>
                    <measurement group_id="B3" value="86.8" spread="20.7"/>
                    <measurement group_id="B4" value="86.8" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C</title>
          <population>All randomized participants with a baseline A1C measurement.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="440"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.81" spread="0.60"/>
                    <measurement group_id="B2" value="7.80" spread="0.60"/>
                    <measurement group_id="B3" value="7.76" spread="0.60"/>
                    <measurement group_id="B4" value="7.79" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sitting Systolic Blood Pressure</title>
          <population>All randomized participants with baseline sitting systolic blood pressure data.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="440"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.2" spread="12.8"/>
                    <measurement group_id="B2" value="130.8" spread="12.4"/>
                    <measurement group_id="B3" value="129.9" spread="12.0"/>
                    <measurement group_id="B4" value="130.3" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Antihyperglycemic (AHA) Medication (Monotherapy or Dual Therapy)</title>
          <population>All randomized participants with information on or baseline data of prior antihyperglycemic medication use</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="441"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Prior Antihyperglycemic Medication</title>
                  <measurement_list>
                    <measurement group_id="B1" value="448"/>
                    <measurement group_id="B2" value="439"/>
                    <measurement group_id="B3" value="437"/>
                    <measurement group_id="B4" value="1324"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Prior Use &amp; Not on Antihyperglycemic Medication</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Data not available</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <population>All randomized and treated participants.</population>
          <units>milliliters/minute/1.73 meters^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="448"/>
                    <count group_id="B2" value="440"/>
                    <count group_id="B3" value="437"/>
                    <count group_id="B4" value="1325"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.3" spread="18.7"/>
                    <measurement group_id="B2" value="86.7" spread="18.3"/>
                    <measurement group_id="B3" value="86.6" spread="18.5"/>
                    <measurement group_id="B4" value="87.2" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach</title>
        <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>All randomized, treated participants with at least one A1C measurement (baseline or a post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach</title>
          <description>A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.</description>
          <population>All randomized, treated participants with at least one A1C measurement (baseline or a post-baseline).</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="440"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" lower_limit="-0.65" upper_limit="-0.47"/>
                    <measurement group_id="O2" value="-0.64" lower_limit="-0.73" upper_limit="-0.55"/>
                    <measurement group_id="O3" value="-0.74" lower_limit="-0.83" upper_limit="-0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is declared if the upper bound of the two-sided 95% confidence interval (CI) for the mean difference is less than 0.3%.</non_inferiority_desc>
            <param_type>Difference in the Least Squares Means</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>Constrained Longitudinal Data Analysis (cLDA) model with fixed effects for treatment, time, prior antihyperglycemic medication (monotherapy or dual therapy), baseline eGFR (continuous) and the interaction of time by treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is declared if the upper bound of the two-sided 95% confidence interval (CI) for the mean difference is less than 0.3%.</non_inferiority_desc>
            <param_type>Difference in the Least Squares means</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
            <estimate_desc>Based on cLDA model with fixed effects for treatment, time, prior antihyperglycemic medication (monotherapy or dual therapy), baseline eGFR (continuous) and the interaction of time by treatment.
Time was treated as a categorical variable.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to Week 106</time_frame>
        <population>All randomized participants who took at least one dose of trial treatment, 10 randomized participants from one trial site were excluded from these analyzes, and one randomized participant did not receive treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>All randomized participants who took at least one dose of trial treatment, 10 randomized participants from one trial site were excluded from these analyzes, and one randomized participant did not receive treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="435"/>
                <count group_id="O3" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1"/>
                    <measurement group_id="O2" value="71.3"/>
                    <measurement group_id="O3" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen &amp; Nurminen method</non_inferiority_desc>
            <param_type>Difference in % vs. Glimepiride</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>7.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen &amp; Nurminen method</non_inferiority_desc>
            <param_type>Difference in % vs. Glimepiride</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104</title>
        <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
        <time_frame>Up to Week 104</time_frame>
        <population>All randomized participants who took at least one dose of trial treatment, 10 randomized participants from one trial site were excluded from these analyzes, and one randomized participant did not receive treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104</title>
          <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
          <population>All randomized participants who took at least one dose of trial treatment, 10 randomized participants from one trial site were excluded from these analyzes, and one randomized participant did not receive treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="445"/>
                <count group_id="O2" value="435"/>
                <count group_id="O3" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs. Glimepiride</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in % vs. Glimepiride</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach</title>
        <description>Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>All randomized participants who took at least one dose of trial treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach</title>
          <description>Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
          <population>All randomized participants who took at least one dose of trial treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="440"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="5.2"/>
                    <measurement group_id="O3" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Based on Miettinen &amp; Nurminen method</method>
            <param_type>Difference in % vs. Glimepiride</param_type>
            <param_value>-14.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.4</ci_lower_limit>
            <ci_upper_limit>-9.8</ci_upper_limit>
            <other_analysis_desc>Based on Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Based on Miettinen &amp; Nurminen method</method>
            <param_type>Difference in % vs. Glimepiride</param_type>
            <param_value>-16.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.3</ci_lower_limit>
            <ci_upper_limit>-12.2</ci_upper_limit>
            <other_analysis_desc>Based on Miettinen &amp; Nurminen method</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach</title>
        <description>This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>All randomized, treated participants with at least one body weight measurement (baseline or a post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach</title>
          <description>This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
          <population>All randomized, treated participants with at least one body weight measurement (baseline or a post-baseline).</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="440"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" lower_limit="-3.31" upper_limit="-2.61"/>
                    <measurement group_id="O2" value="-3.38" lower_limit="-3.73" upper_limit="-3.03"/>
                    <measurement group_id="O3" value="0.91" lower_limit="0.56" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained Longitudinal Data analysis</method>
            <param_type>Difference in LSM vs. Glimepiride</param_type>
            <param_value>-4.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.77</ci_lower_limit>
            <ci_upper_limit>-3.80</ci_upper_limit>
            <estimate_desc>LSM=Least Squares Means</estimate_desc>
            <other_analysis_desc>Constrained Longitudinal Data analysis with fixed effects for treatment, time, interaction of time by treatment, prior antihyperglycemic medication (monotherapy or dual therapy), and baseline eGFR (continuous).</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained Longitudinal Data Analysis</method>
            <param_type>Difference in the LSM vs. Glimepiride</param_type>
            <param_value>-3.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.36</ci_lower_limit>
            <ci_upper_limit>-3.38</ci_upper_limit>
            <other_analysis_desc>Constrained Longitudinal Data Analysis with fixed effects for treatment, time, interaction of time by treatment, prior antihyperglycemic medication (monotherapy or dual therapy), and baseline eGFR (continuous).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach</title>
        <description>This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>All randomized, treated participants with at least one SBP measurement (baseline or a post-baseline).</population>
        <group_list>
          <group group_id="O1">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 15 mg</title>
            <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach</title>
          <description>This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.</description>
          <population>All randomized, treated participants with at least one SBP measurement (baseline or a post-baseline).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="440"/>
                <count group_id="O3" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" lower_limit="-3.36" upper_limit="-1.13"/>
                    <measurement group_id="O2" value="-3.81" lower_limit="-4.91" upper_limit="-2.71"/>
                    <measurement group_id="O3" value="0.95" lower_limit="-0.15" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained Logitudinal Data Analysis</method>
            <param_type>Difference in the LSM vs. Glimepiride</param_type>
            <param_value>-4.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.29</ci_lower_limit>
            <ci_upper_limit>-3.25</ci_upper_limit>
            <other_analysis_desc>Constrained Logitudinal Data Analysis with fixed effects for treatment, time, interaction of time by treatment, prior anthyperglycemic medication (monotherapy or dual therapy), and baseline eGFR (continuous).</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Constrained Logitudinal Data Analysis</method>
            <param_type>Difference in the LSM vs. Glimepiride</param_type>
            <param_value>-3.20</param_value>
            <ci_percent>0.001</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.73</ci_lower_limit>
            <ci_upper_limit>-1.67</ci_upper_limit>
            <other_analysis_desc>Constrained Logitudinal Data Analysis with fixed effects for treatment, time, interaction of time by treatment, prior anthyperglycemic medication (monotherapy or dual therapy), and baseline eGFR (continuous).</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 106</time_frame>
      <desc>The safety analysis population included all randomized participants who took at least one dose of trial treatment, 10 randomized participants from one trial site were excluded from these analyzes, and one randomized participant did not receive treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104</description>
        </group>
        <group group_id="E2">
          <title>Ertugliflozin 15 mg</title>
          <description>Ertugliflozin 15 mg QD from Day 1 to Week 104</description>
        </group>
        <group group_id="E3">
          <title>Glimepiride</title>
          <description>Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Angina pectoris aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Single vessel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Triple vessel disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Chorioretinal folds</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Senile cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ventral hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Weakness generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Chronic calculous cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Jaundice extrahepatic obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Gangrene toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Influenza A virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Purulent appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Recurrent urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Sigmoid diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Knee ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Knee sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lumbar sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lumbar strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lumbosacral (joint) (ligament) sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Malleolar fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Neck strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pertrochanteric fracture of femur, closed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Polytraumatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Shoulder sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Calcifying tendinitis of shoulder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Osteoarthritis aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pain in thigh</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Spinal stenosis NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Vertebral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Breast ductal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cancer of sigmoid colon (excl rectosigmoid)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Intraductal papilloma of breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Metatypical basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Ovarian cystadenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Thyroid papillary carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Tubular adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Uterine fibroids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Multiple cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Depression worsened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Recurrent depressive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic retention of urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Asthma aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Choanal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease exacerbated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Obstructive chronic bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Vocal cord nodule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic peripheral angiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Leg ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="165" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="445"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="435"/>
                <counts group_id="E3" events="24" subjects_affected="22" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="31" subjects_affected="21" subjects_at_risk="445"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="435"/>
                <counts group_id="E3" events="31" subjects_affected="23" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="39" subjects_affected="27" subjects_at_risk="445"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="435"/>
                <counts group_id="E3" events="27" subjects_affected="18" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="445"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="435"/>
                <counts group_id="E3" events="36" subjects_affected="29" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic hypoglycaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="445"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="435"/>
                <counts group_id="E3" events="87" subjects_affected="27" subjects_at_risk="435"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="14" subjects_at_risk="445"/>
                <counts group_id="E2" events="53" subjects_affected="25" subjects_at_risk="435"/>
                <counts group_id="E3" events="470" subjects_affected="82" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="445"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="435"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="435"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

